Biologicals

Influenza

WHO biosafety risk assessment and guidelines for the production and quality control of human influenza vaccines containing the pandemic influenza A H1N1 (2009) virus: Update

H1N1 specific-update of TRS 941, Annex 5

Proposed Guidelines: Regulatory Preparedness for Human Pandemic Influenza Vaccines

WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines

Recommendations for the production and control of influenza vaccine (inactivated)

WHO Technical Report Series, No. 927, 2005, Annex 3

Influenza vaccine, live

Title: Requirements for Influenza Vaccine (Live); Adopted 1978, TRS No 638, Annex 3

NEW PUBLICATIONS

TRS 1004 - WHO Expert Committee on Biological Standardization, Sixty-seventh report

UPCOMING EVENTS


  • WHO Working Group meeting on Respiratory Syncytial Virus (RSV) Vaccine Standardization, WHO headquarters, Geneva, Switzerland, 13-15 September 2017
  • WHO Second Working Group Meeting on Developing WHO Guidelines on safe production of polio vaccines, WHO HQ Salle D, 19-20 September 2017
  • WHO Workshop on Implementation of Good Manufacturing Practices for Biological Products, Bangkok, Thailand 15-17 November 2017
  • WHO Implementation Workshop on the Quality, Safety and Efficacy of Typhoid Conjugate Vaccines, Osong, Chungju-si, The Republic of Korea, 21-13 November 2017

Contacts


Technologies Standards and Norms (TSN)
Essential Medicines and Health Products (EMP)
World Health Organization (WHO)
Avenue Appia 20
1211 Geneva 27, Switzerland
Fax No. +41 22 7914971